当前位置: 首页 >> 检索结果
4241. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.
作者: Andrew W Bradbury.;Catherine A Moakes.;Matthew Popplewell.;Lewis Meecham.;Gareth R Bate.;Lisa Kelly.;Ian Chetter.;Athanasios Diamantopoulos.;Arul Ganeshan.;Jack Hall.;Simon Hobbs.;Kim Houlind.;Hugh Jarrett.;Suzanne Lockyer.;Jonas Malmstedt.;Jai V Patel.;Smitaa Patel.;S Tawqeer Rashid.;Athanasios Saratzis.;Gemma Slinn.;D Julian A Scott.;Hany Zayed.;Jonathan J Deeks.; .
来源: Lancet. 2023年401卷10390期1798-1809页
Chronic limb-threatening ischaemia is the severest manifestation of peripheral arterial disease and presents with ischaemic pain at rest or tissue loss (ulceration, gangrene, or both), or both. We compared the effectiveness of a vein bypass first with a best endovascular treatment first revascularisation strategy in terms of preventing major amputation and death in patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion.
4242. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Harry P Erba.;Pau Montesinos.;Hee-Je Kim.;Elżbieta Patkowska.;Radovan Vrhovac.;Pavel Žák.;Po-Nan Wang.;Tsvetomir Mitov.;James Hanyok.;Yasser Mostafa Kamel.;Jaime E Connolly Rohrbach.;Li Liu.;Aziz Benzohra.;Arnaud Lesegretain.;Jorge Cortes.;Alexander E Perl.;Mikkael A Sekeres.;Hervé Dombret.;Sergio Amadori.;Jianxiang Wang.;Mark J Levis.;Richard F Schlenk.; .
来源: Lancet. 2023年401卷10388期1571-1583页
Patients with acute myeloid leukaemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus chemotherapy showed antitumour activity with an acceptable safety profile in patients with FLT3-ITD-positive newly diagnosed AML. The aim of the study was to compare the effect of quizartinib versus placebo on overall survival in patients with FLT3-ITD-positive newly diagnosed AML aged 18-75 years.
4245. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
作者: Adèle de Masson.;Marie Beylot-Barry.;Caroline Ram-Wolff.;Jean-Baptiste Mear.;Stéphane Dalle.;Michel d'Incan.;Saskia Ingen-Housz-Oro.;Corentin Orvain.;Julie Abraham.;Olivier Dereure.;Amandine Charbonnier.;Jérôme Cornillon.;Christine Longvert.;Stéphane Barete.;Serge Boulinguez.;Ewa Wierzbicka-Hainaut.;François Aubin.;Marie-Thérèse Rubio.;Marc Bernard.;Aline Schmidt-Tanguy.;Roch Houot.;Anne Pham-Ledard.;David Michonneau.;Pauline Brice.;Hélène Labussière-Wallet.;Jean-David Bouaziz.;Florent Grange.;Hélène Moins-Teisserenc.;Katayoun Jondeau.;Laurence Michel.;Samia Mourah.;Maxime Battistella.;Etienne Daguindau.;Michael Loschi.;Alexandra Picard.;Nathalie Franck.;Natacha Maillard.;Anne Huynh.;Stéphanie Nguyen.;Ambroise Marçais.;Guillaume Chaby.;Patrice Ceballos.;Yannick Le Corre.;Sébastien Maury.;Jacques-Olivier Bay.;Henri Adamski.;Emmanuel Bachy.;Edouard Forcade.;Gérard Socié.;Martine Bagot.;Sylvie Chevret.;Régis Peffault de Latour.; .; .; .
来源: Lancet. 2023年401卷10392期1941-1950页
Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs.
4249. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
作者: Ornella Verrastro.;Simona Panunzi.;Lidia Castagneto-Gissey.;Andrea De Gaetano.;Erminia Lembo.;Esmeralda Capristo.;Caterina Guidone.;Giulia Angelini.;Francesco Pennestrì.;Luca Sessa.;Fabio Maria Vecchio.;Laura Riccardi.;Maria Assunta Zocco.;Ivo Boskoski.;James R Casella-Mariolo.;Pierluigi Marini.;Maurizio Pompili.;Giovanni Casella.;Enrico Fiori.;Francesco Rubino.;Stefan R Bornstein.;Marco Raffaelli.;Geltrude Mingrone.
来源: Lancet. 2023年401卷10390期1786-1797页
Observational studies suggest that bariatric-metabolic surgery might greatly improve non-alcoholic steatohepatitis (NASH). However, the efficacy of surgery on NASH has not yet been compared with the effects of lifestyle interventions and medical therapy in a randomised trial.
4250. Ferric carboxymaltose versus standard-of-care oral iron to treat second-trimester anaemia in Malawian pregnant women: a randomised controlled trial.
作者: Sant-Rayn Pasricha.;Martin N Mwangi.;Ernest Moya.;Ricardo Ataide.;Glory Mzembe.;Rebecca Harding.;Truwah Zinenani.;Leila M Larson.;Ayse Y Demir.;William Nkhono.;Jobiba Chinkhumba.;Julie A Simpson.;Danielle Clucas.;William Stones.;Sabine Braat.;Kamija S Phiri.
来源: Lancet. 2023年401卷10388期1595-1609页
Anaemia affects 46% of pregnancies in Africa; oral iron is recommended by WHO but uptake and adherence are suboptimal. We tested a single dose of a modern intravenous iron formulation, ferric carboxymaltose, for anaemia treatment in Malawian pregnant women.
4253. Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease.
作者: Marwa Hakimi.;Jeffrey P North.;Mark A Taylor.;Ashley Hailer.;Yale Liu.;Esther Kim.;Kerstin Morehead.;Kanade Shinkai.;Tina Bhutani.;Jeffrey B Cheng.;Raymond J Cho.
来源: Lancet. 2023年401卷10385期1381页 |